Skip to main content
2024 ACRM Annual Fall Conference & EXPO Main banner
G4 Foot Drop System
REGISTER NOW
REGISTER NOW
Final Program


AT-A-GLANCE PDF
Back
Register Now

Symposium

Telehealth

Brain Injury

Neuroplasticity

Rehabilitation Treatment Specification System

Stroke

Technology

Enhancing UE Functionality with Vivistim Therapy in Patients After Stroke; Success Stories and Digital Health Future 9644

Friday, November 1, 2024
8:15 AM – 9:15 AM  
Location:  Parkview (Verandah Building)
Credit Hours: Not Eligible for CE Credit
Vivistim is the first FDA-approved neurostimulation device to pair VNS with rehabilitation therapy and daily activities. This pairing helps strengthen the brain connections needed to improve hand and arm function. The Vivistim System is designed to help increase neuroplasticity to help regain your hand and arm movements.
In this symposium, we will address the emerging use of both the microtransponder and ViviStim therapy as an intervention specialty by Occupational Therapists with patients of stroke is demonstrating increased and enhanced upper extremity function for various performance areas and increasing the quality of life through successful clinical outcomes. We will learn from the patients themselves how the implanted microtransponder and ViviStim works for them and how it’s impacted their life. In addition, the discussion will examine the benefits of implementing future digital health components to facilitate better adherence to the home exercise program and increased clinical outcomes in the home setting.

Learning Objectives:

  • Identify what is the Microtransponder and Vivistim therapy emerging as a intervention for patients after Stroke
  • Determine the type of patient after stroke, evaluations, intervention types and potential therapeutic outcomes with Vivistim therapy
  • Describe how emerging digital health strategies can impact sustainable technology assisted interventions for service expansion and better patient home exercise adherence and outcomes after stroke
  • Identify what is the Microtransponder and Vivistim therapy emerging as a intervention for patients after Stroke
Disclosure(s):
Tammy Richmond, MS, OTRL, FAOTA: No financial relationships to disclose
Cecilia N. Prudente, PhD, PT: MicroTransponder Inc.: Employment (full or part time) (Ongoing), Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing)